Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor
Checkpoint inhibitors (eg, programmed cell death protein 1 [PD-1], programmed cell death ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4] antibodies) are changing how we understand cancer and provide a means to develop modern immunotherapies. An emergent notion relates success...
Gespeichert in:
| Veröffentlicht in: | The Annals of thoracic surgery 2017-04, Vol.103 (4), p.1340-1349 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1349 |
|---|---|
| container_issue | 4 |
| container_start_page | 1340 |
| container_title | The Annals of thoracic surgery |
| container_volume | 103 |
| creator | Dhupar, Rajeev, MD Van Der Kraak, Lauren, PhD Pennathur, Arjun, MD Schuchert, Matthew J., MD Nason, Katie S., MD Luketich, James D., MD Lotze, Michael T., MD |
| description | Checkpoint inhibitors (eg, programmed cell death protein 1 [PD-1], programmed cell death ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4] antibodies) are changing how we understand cancer and provide a means to develop modern immunotherapies. An emergent notion relates success with checkpoint inhibitors with high mutational load tumors. There are few studies that examine checkpoint protein expression and relate these to clinical outcomes after the conventional treatment of patients with esophageal cancer, which has a high mutational load. The objective of this review is to summarize the literature that examines checkpoint expression and clinical outcomes, as well as propose an accelerated approach to introducing these therapies into the clinic to treat patients with esophageal cancer. |
| doi_str_mv | 10.1016/j.athoracsur.2016.12.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1883180847</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0003497516318240</els_id><sourcerecordid>1883180847</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495t-f367d9b6dd3b4a81918a69f74f34adaadeabb2be7bf61ff782df6ffe144f00753</originalsourceid><addsrcrecordid>eNqNkcGO0zAQhi0EYsvCKyAfuSTYjpM4HJCWamFXKgKJcrYm9rh1N4mLnSDt2_AsPBmuuoDEiZM1nv-f0f8NIZSzkjPevD6UMO9DBJOWWIr8U3JRMs4fkRWva1E0ou4ekxVjrCpk19YX5FlKh1yK3H5KLoSq6k62fEU-byHucPbTjt6O4zIhXe_R3B2Dn-ZE_USvUzjuYYcw0DVMBuMbekVv_G5PPy4zzD5MubMJYH_-2C5jiM_JEwdDwhcP7yX5-v56u74pNp8-3K6vNoWRXT0Xrmpa2_WNtVUvQfGOK2g610pXSbAAFqHvRY9t7xruXKuEdY1zyKV0jLV1dUleneceY_i2YJr16JPBYYAJw5I0V6riiinZZqk6S00MKUV0-hj9CPFec6ZPPPVB_-WpTzw1FzrzzNaXD1uWfkT7x_gbYBa8OwswZ_3uMepkPGZO1kc0s7bB_8-Wt_8MMYOfvIHhDu8xHcISM-WcSads0F9Odz2dlTc5opCs-gXP9KJb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1883180847</pqid></control><display><type>article</type><title>Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Dhupar, Rajeev, MD ; Van Der Kraak, Lauren, PhD ; Pennathur, Arjun, MD ; Schuchert, Matthew J., MD ; Nason, Katie S., MD ; Luketich, James D., MD ; Lotze, Michael T., MD</creator><creatorcontrib>Dhupar, Rajeev, MD ; Van Der Kraak, Lauren, PhD ; Pennathur, Arjun, MD ; Schuchert, Matthew J., MD ; Nason, Katie S., MD ; Luketich, James D., MD ; Lotze, Michael T., MD</creatorcontrib><description>Checkpoint inhibitors (eg, programmed cell death protein 1 [PD-1], programmed cell death ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4] antibodies) are changing how we understand cancer and provide a means to develop modern immunotherapies. An emergent notion relates success with checkpoint inhibitors with high mutational load tumors. There are few studies that examine checkpoint protein expression and relate these to clinical outcomes after the conventional treatment of patients with esophageal cancer, which has a high mutational load. The objective of this review is to summarize the literature that examines checkpoint expression and clinical outcomes, as well as propose an accelerated approach to introducing these therapies into the clinic to treat patients with esophageal cancer.</description><identifier>ISSN: 0003-4975</identifier><identifier>EISSN: 1552-6259</identifier><identifier>DOI: 10.1016/j.athoracsur.2016.12.011</identifier><identifier>PMID: 28359471</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>B7-H1 Antigen - metabolism ; Biomarkers - metabolism ; Cardiothoracic Surgery ; CTLA-4 Antigen - metabolism ; Esophageal Neoplasms - etiology ; Esophageal Neoplasms - metabolism ; Esophageal Neoplasms - pathology ; Humans ; Programmed Cell Death 1 Receptor - metabolism ; Surgery ; Tumor Burden</subject><ispartof>The Annals of thoracic surgery, 2017-04, Vol.103 (4), p.1340-1349</ispartof><rights>The Society of Thoracic Surgeons</rights><rights>2017 The Society of Thoracic Surgeons</rights><rights>Copyright © 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c495t-f367d9b6dd3b4a81918a69f74f34adaadeabb2be7bf61ff782df6ffe144f00753</citedby><cites>FETCH-LOGICAL-c495t-f367d9b6dd3b4a81918a69f74f34adaadeabb2be7bf61ff782df6ffe144f00753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28359471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dhupar, Rajeev, MD</creatorcontrib><creatorcontrib>Van Der Kraak, Lauren, PhD</creatorcontrib><creatorcontrib>Pennathur, Arjun, MD</creatorcontrib><creatorcontrib>Schuchert, Matthew J., MD</creatorcontrib><creatorcontrib>Nason, Katie S., MD</creatorcontrib><creatorcontrib>Luketich, James D., MD</creatorcontrib><creatorcontrib>Lotze, Michael T., MD</creatorcontrib><title>Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor</title><title>The Annals of thoracic surgery</title><addtitle>Ann Thorac Surg</addtitle><description>Checkpoint inhibitors (eg, programmed cell death protein 1 [PD-1], programmed cell death ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4] antibodies) are changing how we understand cancer and provide a means to develop modern immunotherapies. An emergent notion relates success with checkpoint inhibitors with high mutational load tumors. There are few studies that examine checkpoint protein expression and relate these to clinical outcomes after the conventional treatment of patients with esophageal cancer, which has a high mutational load. The objective of this review is to summarize the literature that examines checkpoint expression and clinical outcomes, as well as propose an accelerated approach to introducing these therapies into the clinic to treat patients with esophageal cancer.</description><subject>B7-H1 Antigen - metabolism</subject><subject>Biomarkers - metabolism</subject><subject>Cardiothoracic Surgery</subject><subject>CTLA-4 Antigen - metabolism</subject><subject>Esophageal Neoplasms - etiology</subject><subject>Esophageal Neoplasms - metabolism</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Humans</subject><subject>Programmed Cell Death 1 Receptor - metabolism</subject><subject>Surgery</subject><subject>Tumor Burden</subject><issn>0003-4975</issn><issn>1552-6259</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkcGO0zAQhi0EYsvCKyAfuSTYjpM4HJCWamFXKgKJcrYm9rh1N4mLnSDt2_AsPBmuuoDEiZM1nv-f0f8NIZSzkjPevD6UMO9DBJOWWIr8U3JRMs4fkRWva1E0ou4ekxVjrCpk19YX5FlKh1yK3H5KLoSq6k62fEU-byHucPbTjt6O4zIhXe_R3B2Dn-ZE_USvUzjuYYcw0DVMBuMbekVv_G5PPy4zzD5MubMJYH_-2C5jiM_JEwdDwhcP7yX5-v56u74pNp8-3K6vNoWRXT0Xrmpa2_WNtVUvQfGOK2g610pXSbAAFqHvRY9t7xruXKuEdY1zyKV0jLV1dUleneceY_i2YJr16JPBYYAJw5I0V6riiinZZqk6S00MKUV0-hj9CPFec6ZPPPVB_-WpTzw1FzrzzNaXD1uWfkT7x_gbYBa8OwswZ_3uMepkPGZO1kc0s7bB_8-Wt_8MMYOfvIHhDu8xHcISM-WcSads0F9Odz2dlTc5opCs-gXP9KJb</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Dhupar, Rajeev, MD</creator><creator>Van Der Kraak, Lauren, PhD</creator><creator>Pennathur, Arjun, MD</creator><creator>Schuchert, Matthew J., MD</creator><creator>Nason, Katie S., MD</creator><creator>Luketich, James D., MD</creator><creator>Lotze, Michael T., MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170401</creationdate><title>Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor</title><author>Dhupar, Rajeev, MD ; Van Der Kraak, Lauren, PhD ; Pennathur, Arjun, MD ; Schuchert, Matthew J., MD ; Nason, Katie S., MD ; Luketich, James D., MD ; Lotze, Michael T., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495t-f367d9b6dd3b4a81918a69f74f34adaadeabb2be7bf61ff782df6ffe144f00753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>B7-H1 Antigen - metabolism</topic><topic>Biomarkers - metabolism</topic><topic>Cardiothoracic Surgery</topic><topic>CTLA-4 Antigen - metabolism</topic><topic>Esophageal Neoplasms - etiology</topic><topic>Esophageal Neoplasms - metabolism</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Humans</topic><topic>Programmed Cell Death 1 Receptor - metabolism</topic><topic>Surgery</topic><topic>Tumor Burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dhupar, Rajeev, MD</creatorcontrib><creatorcontrib>Van Der Kraak, Lauren, PhD</creatorcontrib><creatorcontrib>Pennathur, Arjun, MD</creatorcontrib><creatorcontrib>Schuchert, Matthew J., MD</creatorcontrib><creatorcontrib>Nason, Katie S., MD</creatorcontrib><creatorcontrib>Luketich, James D., MD</creatorcontrib><creatorcontrib>Lotze, Michael T., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of thoracic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dhupar, Rajeev, MD</au><au>Van Der Kraak, Lauren, PhD</au><au>Pennathur, Arjun, MD</au><au>Schuchert, Matthew J., MD</au><au>Nason, Katie S., MD</au><au>Luketich, James D., MD</au><au>Lotze, Michael T., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor</atitle><jtitle>The Annals of thoracic surgery</jtitle><addtitle>Ann Thorac Surg</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>103</volume><issue>4</issue><spage>1340</spage><epage>1349</epage><pages>1340-1349</pages><issn>0003-4975</issn><eissn>1552-6259</eissn><abstract>Checkpoint inhibitors (eg, programmed cell death protein 1 [PD-1], programmed cell death ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4] antibodies) are changing how we understand cancer and provide a means to develop modern immunotherapies. An emergent notion relates success with checkpoint inhibitors with high mutational load tumors. There are few studies that examine checkpoint protein expression and relate these to clinical outcomes after the conventional treatment of patients with esophageal cancer, which has a high mutational load. The objective of this review is to summarize the literature that examines checkpoint expression and clinical outcomes, as well as propose an accelerated approach to introducing these therapies into the clinic to treat patients with esophageal cancer.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>28359471</pmid><doi>10.1016/j.athoracsur.2016.12.011</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4975 |
| ispartof | The Annals of thoracic surgery, 2017-04, Vol.103 (4), p.1340-1349 |
| issn | 0003-4975 1552-6259 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1883180847 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | B7-H1 Antigen - metabolism Biomarkers - metabolism Cardiothoracic Surgery CTLA-4 Antigen - metabolism Esophageal Neoplasms - etiology Esophageal Neoplasms - metabolism Esophageal Neoplasms - pathology Humans Programmed Cell Death 1 Receptor - metabolism Surgery Tumor Burden |
| title | Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A11%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20Immune%20Checkpoints%20in%20Esophageal%20Cancer:%20A%20High%20Mutational%20Load%C2%A0Tumor&rft.jtitle=The%20Annals%20of%20thoracic%20surgery&rft.au=Dhupar,%20Rajeev,%20MD&rft.date=2017-04-01&rft.volume=103&rft.issue=4&rft.spage=1340&rft.epage=1349&rft.pages=1340-1349&rft.issn=0003-4975&rft.eissn=1552-6259&rft_id=info:doi/10.1016/j.athoracsur.2016.12.011&rft_dat=%3Cproquest_cross%3E1883180847%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1883180847&rft_id=info:pmid/28359471&rft_els_id=S0003497516318240&rfr_iscdi=true |